

LEARNER NOTIFICATION

Society of Cardiovascular Magnetic Resonance

Meeting Title: 28th Annual Scientific Sessions

Meeting Dates January 29 through February 1, 2025

Location: Washington, DC, USA

Format (Live, In-Person) (Live-Streaming)

Acknowledgement of Financial Commercial Support

No monetary support for this CME educational activity in the form of unrestricted educational grants.

Acknowledgement of In-Kind Support

No in-kind support was received for this educational activity.



Accreditation Statement

The Society of Cardiovascular Magnetic Resonance (SCMR) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statements*

For Live/In-Person Attendance:

SCMR designates this live, in-person activity for a maximum of 24.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Live/Streaming Attendance:

SCMR designates this live, online activity for a maximum of 18.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Statements

American Board of Internal Medicine (ABIM):

The activity is directly or jointly provided by an organization accredited in good standing within the ACCME System. The activity is planned in the context of one or more of the ABMS/ACGME competencies.

All CME sessions are eligible for ABIM MOC credit. On the post activity evaluation, learners can indicate if they want to have credits posted in the ACCME PARS system for awarded MOC credit. Participation in this CME activity enables attendees to earn up to **24.00 MOC points** in the ABIM Maintenance of Certification (MOC) program. Points are equivalent to the number of CME credits claimed. You must provide your ABIM Member #, State of Licensure, and DOB (Month & Day only) in order to have your credits reported to the Board.

American Board of Pediatrics (ABP):

Participation in this CME activity enables attendees to earn up to 10.5 MOC points. To earn credit, participants must complete the post-activity evaluation and associated quizzes, achieving a threshold score of 75% or higher. MOC credit will be issued based on the number of successfully completed sessions. You must provide your ABP Member #, State of Licensure, and DOB (Month & Day only) in order to have your credits reported to the Board.

Sessions for ABP MOC

| Session Title | Credits |
|---|-----------|
| | Available |
| Preconference Session 1: The New Bread and Butter | 1.75 |
| Preconference Session 2: Technical Challenges & Advanced | 1.75 |
| Techniques | |
| Preconference Session 3: RVs Gone Bad | 1.0 |
| Preconference Session 4: Single Ventricles: CMR from Infancy to | 1.0 |
| Adulthood | |
| Preconference Session 5: Pediatric Cardiomyopathy | 1.0 |
| Preconference Session 6: Pediatric Vascular Disease | 1.0 |
| Session 1: It's All a Bit Borderline | 1.0 |
| Session 2: Future Proofing PCHD CMR Services | 1.0 |
| Session 4: SIG3D+ | 1.0 |
| Session 5: Fetal CMR | 1.0 |

Designated sessions are eligible to earn APB MOC Credit. On the post activity evaluation, learners can indicate if they want to have credits posted in the ACCME PARS system for awarded MOC credit. For satisfactory completion to earn credit, if you check the box for ABP MOC credit, you will receive a link to complete a post test for each session you indicate that you attended. You must pass each posttest with a threshold of 75%. Quizzes can be retaken up to three times to achieve the threshold. MOC credit is issued based on the number of successfully passed quizzes.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit. By providing your information you grant SCMR permission to report your CME/MOC hours to the ACCME and/or other boards as applicable.

Satisfactory Completion/CME/MOC

To claim credit for a live SCMR CME event, you must complete the meeting evaluations. CME certificates will be provided upon completion of the online meeting evaluation, the system will save your certificate so that you can print it later, or you can send a copy of the certificate to yourself as an e-mail attachment. All registered participants will receive an email after conference with information on how to claim credit.

American Society of Radiologic Technologists (ASRT):

This activity has been approved for up to 6.0 ASRT Category A credits. To claim credit, participants must:

- 1. Attend the session(s) in full for which credit is sought. See chart below.
- 2. Scan badge in session room.
- 3. Complete the post-activity evaluation.
- 4. Certificates will be available upon submission of the evaluation.

| Reference No. | Cat. | Activity Title | Start Date | Expires | Credit |
|---------------|------|---|------------|----------|--------|
| ILD00150015 | А | CMR Scanning A Practical Guide | 1/30/2025 | 2/2/2025 | 1 |
| ILD00150016 | А | CMR Hardware Equipment/Devices/Sustainability | 1/30/2025 | 2/2/2025 | 1 |
| ILD00150017 | А | CMR FOR TECHNOLOGIST | 1/30/2025 | 2/2/2025 | 1 |

| ILD00150018 | А | Career Development for Technologists | 1/30/2025 | 2/2/2025 | 1 |
|-------------|---|--|-----------|----------|---|
| ILD00150019 | A | Oral Abstract for Presentation and a Guide to Write an Abstract | 1/30/2025 | 2/2/2025 | 1 |
| ILD00150020 | А | Oral Case Presentations & Guide to Write a Case | 1/30/2025 | 2/2/2025 | 1 |

^{*}Credit information subject to change.

Please contact via email at education@scmr.org with questions.

Educational Information

Physician Practice Gap: New advanced technology for CMR is being developed rapidly and research is demonstrating the clinical utility of CMR for multiple cardiac pathologies. There is slow uptake of the new applications and techniques, and communication of ongoing research. Training gaps have widened for physicians in practice regarding knowledge of these new techniques and how to use them clinically. The ideal future state is that we would have a more educated CMR imaging workforce both in terms of technical development and clinical applications that are rapidly translated into clinical practice to optimize clinical care.

Learning Needs that Underly the Practice Gap: Practitioners need education on how to identify, diagnose and treat various issues and complications associated with cardiovascular disease with CMR, new approaches, strategies and updated practice guidelines and data to better diagnose and treat cardiovascular disease with CMR, and instruction and access to new and emerging technologies in the MR imaging diagnosis of cardiovascular disease.

Learning Objectives

Describe new applications for identification of cardiac pathologies.

- Discuss emerging research as it applies to technical development and clinical applications in CMR
- · Apply updated CMR techniques in the clinical setting

DESIGNED to Change/Outcome: This CME activity is designed to change learner knowledge, competence and performance in the identification, diagnosis, and treatment of cardiovascular conditions following updated practice guidelines in CMR to lead to improved patient outcomes.

Disclosure of Financial Relationships and Mitigation of Relevant Financial Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, all individuals in a position to influence or control the content of this CME activity have disclosed all financial relationships with ineligible companies. An ineligible company is defined by ACCME as an entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. A rigorous review process has been conducted to identify, assess, and mitigate any relevant financial conflicts of interest. The following disclosures reflect financial relationships reported by faculty, planners, reviewers, and other individuals involved in this activity. Any conflicts of interest have been resolved through appropriate mitigation strategies, such as content peer review, recusal from relevant planning or decision—making, or independent validation of research findings. It is the policy of this CME provider to ensure that all educational activities are evidence—based, balanced, and free from commercial bias. Learners are encouraged to critically evaluate the information presented and consider multiple sources of evidence when applying knowledge to clinical practice.

A complete list of disclosures is provided below. If an individual is not listed, they have no relevant financial relationships to disclose.

Financial Relationships - Planners

| Name of Individual | Individual's Role(s) in the Activity | Nature of Commercial Interest(s) | Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity. |
|--------------------|---|---|--|
| Addetia, Karima | Planning Committee | Pfizer, Research Grant Site Principal Investigator | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |

| Allen, Bradley | Planning Committee | Imaging, Medscape, Guerbet, MRI Online, Consultant, Speakers Bureau, Research Grant Overall Principal Investigator, Private Stock Shareholder, Speakers Bureau | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
|-------------------|---|--|--|
| Ennis, Daniel | Speaker, Reviewer, Planner, Chair, Co-Author, Moderator, Planning Committee | GE Healthcare, Research Grant Site Principal Investigator | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Ferreira, Vanessa | Speaker, Chair, Planning Committee | General Electric Healthcare, Research Grant Site Principal Investigator | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Fontana, Marianna | Speaker | Consultancy/advisoy boards for Alnylam, Alexion, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia, Ionis, Cardior, Lexeo, Pfizer. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfize, Shares: Lexeo/onsultant, Private Stock Shareholder | The SCMR COI Subcommittee directed peer review of this individual's participation in planning content to avoid bias. |

| Hanneman, Kate | Speaker, Reviewer, Planner, Planning Committee | Sanofi Genzyme, Speaker's Bureau | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
|----------------|---|--|--|
| Hu, Peng | Planning Committee | United Imaging, Consultant | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Knight, Dan | Planning Committee | Janssen Pharmaceuticals, Speakers Bureau | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Lamb, Hildo | Speaker, Reviewer, Planner, Chair, Co-Author, Moderator, Planning Committee | Royal Philips, Consultant | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Manka, Robert | Speaker, Planning Committee | Philips Healthcare/Tomtec Imaging,Bayer (Schweiz) AG,Siemens,Bristol Myers Squibb/Speakers Bureau,Speakers Bureau,Speakers Bureau,Speakers Bureau,Speakers | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |

| Markl, Michael | Planning Committee | Siemens, Research Grant Site Principal Investigator | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
|-------------------|---|--|--|
| Mukai, Kanae | Speaker, Planner | Canon Medical Systems, Speakers Bureau | The SCMR COI Subcommittee directed peer review of this individual's participation in planning content to avoid bias. |
| Ng, Ming Yen | Speaker, Planner, Chair | GE,BAYER, other, other | The SCMR COI Subcommittee directed peer review of this individual's participation in planning content to avoid bias. |
| Patel, Amit | Planning Committee | Siemens Healthineers, GE healthcare, Neosoft /Other, Research Grant Overall Principal Investigator, Other | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Rajiah, Prabhakar | Speaker, Reviewer, Planner, Moderator, Planning Committee | Elsevier, Other | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |

| Rizzi Coelho-Filho, Otavio | Planner, Co-Author, Planning Committee | Bayer,Astra Zeneca,Pfizer,BMS/Scientific/M edical Advisory Board Member,Scientific/Medical Advisory Board Member,Speakers Bureau,Scientific/Medical Advisory Board Member | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
|-------------------------------|---|---|--|
| Robinson, Joshua | Planning Committee | Siemens Medical Solutions USA, Inc,Doximity, Inc/Consultant,Public Stock Shareholder | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Rochitte, Carlos | Planning Committee | Pfizer, Other | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Seiberlich, Nicole | Planning Committee | Siemens Healthineers, Research Grant Site Principal Investigator | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |
| Varga-Szemes, Akos | Planning Committee | Siemens,Siemens,Elucid Bioimaging,Elucid Bioimaging, Research Grant Overall Principal Investigator,Speakers Bureau,Consultant | The SCMR COI Subcommittee instructed recusal from planning decisions related to disclosed financial relationships. |

Disclosure of Financial Relationships - Faculty

The following serving as moderators, speakers/presenters, or reviewers (judges) who are in control of content have indicated that they do have financial relationships with ACCME defined ineligible companies within the past 24 months. All financial relationships have been mitigated. Those that have indicated an employee or ownership relationship (including privately held stock, royalty, intellectual property, etc.) with an ACCME defined ineligible company.

| Name of Individual | Individual's Role(s) in the Activity | Nature of Commercial Interest(s) | Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity. |
|--------------------|---|--|---|
| Allen, Bradley | Role: Moderator, Session: Closing Plenary and Awards, Presentation: Award Ceremony Role: Moderator, Session: Closing Plenary and Awards, Presentation: Closing Remarks Role: Moderator, Session: Early Career Award Clinical, Presentation: Early Career Award Clinical Role: Moderator, Session: Focus Session: Efficient CMR, Presentation: Focus Session: Efficient CMR Role: Moderator, Session: Opening Plenary Session, Presentation: What to | Medscape (Speakers Bureau) Guerbet (Research Grant Overall Principal Investigator) Third Coast Dynamics (Private Stock Shareholder) MRI Online (Speakers Bureau) Siemens (Other) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

expect at SCMR 2025

Role: Planning Committee,

Session: Closing Plenary and

Awards, Presentation:

Award Ceremony, Speaker

Role: Planning Committee,

Session: Closing Plenary and

Awards, Presentation:

Closing Remarks | Role:

Planning Committee,

Session: Early Career Award

Clinical, Presentation: Early

Career Award Clinical | Role:

Planning Committee,

Session: Focus Session:

Efficient CMR, Presentation:

Focus Session: Efficient CMR

Role: Planning Committee,

Session: Opening Plenary

Session, Presentation: What

to expect at SCMR 2025

Role: Speaker, Session:

Closing Plenary and Awards,

Presentation: Award

Ceremony | Role: Speaker,

Session: Closing Plenary and

Awards, Presentation:

Closing Remarks | Role: Speaker, Session: Early Career Award Clinical,

Presentation: Early Career

Award Clinical | Role: Speaker, Session: Focus Session: Efficient CMR,

Presentation: Focus Session:

Efficient CMR | Role:

Speaker, Session: Opening

Plenary Session,

Presentation: What to expect at SCMR 2025

| Atkinson, Daniel | Speaker: Rapid Fire 10- | GE Healthcare (Other) | Upon review by the COI subcommittee, |
|------------------|---------------------------|-----------------------|--|
| | Miscellaneous III Kiosk 3 | | this individual's relationships were not |
| | Effects of software on | | perceived to present a conflict of interest. |
| | myocardial T1 | | They were asked to attest to several |
| | measurements: a 3 T | | statements regarding adherence to |
| | multicentre single vendor | | ACCME standards and guidelines, to |
| | phantom study | | make full disclosure to learners, and to |
| | | | avoid any perception of bias in any of |
| | | | their roles on this program. |

Backhaus, Soren Role: Speaker Rapid Fire 5-Miscellaneous 2 Kiosk 3 Left ventricular deformation predicts major adverse cardiac events following acute myocardial infarction independently of afterload and ventriculi-arterial coupling, Rapid Fire 6 -Valvular Heart Disease II Kiosk 5 Impact of Pulmonary Stenosis vs. Regurgitation on Strain and Strain Rate using Cardiac Magnetic Resonance Feature Tracking in a Porcine Model, Rapid Fire 3, Interventional MRI Kiosk 6 A Report of >2000 Consecutive Patients Undergoing Imaging with Pacemakers and ICDs in the MRI

Environment; the Additive

~20-Year Observational

Study

Value of a Large, Prospective

Corvia Medical (Other)

Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program.

| Biederman, Robert | Speaker: Rapid Fire 10- Sustainability & CMR and Miscellaneous Kiosk 5 The Mixing Enigma? Does Interchanging Leads and Generators Still Cause Concern in the MRI? Could this be the Final Device Hurdle for Routine MRI | Bms (Scientific/Medical Advisory Board Member); Lantheus (Speakers Bureau); Janssen (Speakers Bureau); Kiniksa (Speakers Bureau); Bracco (Speakers Bureau) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
|-------------------|---|---|---|
| Biederman, Robert | Patients? Speaker: Rapid Fire 3- Interventional MRI Kiosk 6 | Bms (Speakers Bureau) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| Bucciarelli-Ducci, | Role: Speaker, Moderator, | Bayer (Speakers Bureau) GE | Upon review by the COI subcommittee, |
|--------------------|-------------------------------|----------------------------------|--|
| Chiara | Session: Clinical & | HealthCare (Speakers Bureau) | this individual's relationships were not |
| | Translation 8: Her Heart | Philips (Speakers Bureau) | perceived to present a conflict of interest. |
| | Unveiled: Exploring CMR in | | They were asked to attest to several |
| | Women's Heart Disease, | | statements regarding adherence to |
| | Presentation: Microvascular | | ACCME standards and guidelines, to |
| | disease: CMR rocks Role: | | make full disclosure to learners, and to |
| | Speaker, Moderator, Session: | | avoid any perception of bias in any of |
| | SCMR Annual Assembly, | | their roles on this program. |
| | Presentation: Annual Report | | |
| | Role: Speaker, Moderator, | | |
| | Session: SCMR Annual | | |
| | Assembly, Presentation: | | |
| | Educational Program | | |
| | 2025-2026 Role: | | |
| | Speaker, Moderator, Session: | | |
| | SCMR Annual Assembly, | | |
| | Presentation: No | | |
| | presentation title provided | | |
| Carr, James | Role: Speaker, Session: | Siemens (Research Grant Site | Upon review by the COI subcommittee, |
| | Clinical & Translation: Cost- | Principal Investigator) Bracco | this individual's relationships were not |
| | effectiveness, Billing and | (Scientific/Medical Advisory | perceived to present a conflict of interest. |
| | Workforce (joint with IACI), | Board Member) RoClub | They were asked to attest to several |
| | Presentation: Is CMR cost- | (Scientific/Medical Advisory | statements regarding adherence to |
| | effective? An Administrative | Board Member) Bayer | ACCME standards and guidelines, to |
| | Perspective | (Research Grant Site Principal | make full disclosure to learners, and to |
| | | Investigator) Bayer | avoid any perception of bias in any of |

| | | (Scientific/Medical Advisory Board Member) Bayer (Speakers Bureau) Guerbet (Research Grant Site Principal Investigator) | their roles on this program. |
|-------------------|--|--|---|
| Chiribiri, Amedeo | Role: Speaker, Moderator, Session: Focus Session: Accessible CMR, Presentation: Discussion Role: Speaker, Moderator, Session: Rapid Fire 7- Quantitative Perfusion II Kiosk 6, Presentation: Rapid Fire 7- Quantitative Perfusion II Kiosk 6 | GE Healthcare (Consultant) Siemens Healthineers (Patent Holder) Philips Healthcare (Patent Holder) Siemens Healthineers (Research Grant Site Principal Investigator) Philips Healthcare (Research Grant Site Principal Investigator) | Upon review by the COI subcommittee, this individual's relationships, while it was determined that there is a low risk of confilct of intersest based on the content, a room monitor will be assigned as an extra precaution to ensure avoidance of bias. |
| Cook, Tessa | Speaker: Clinical & Translation 2: Climate Change, Environmental Sustainability and CMR Strategies to Reduce the Environmental Impact of CMR | Bayer (Consultant) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| Detterich, Jon | Speaker Initial Experience – Clinical Application and Scoring System of Real– Time Fetal Cardiac Magnetic Resonance at 0.55T | Alcor Scientific (Research Grant Site Principal Investigator) | Upon review by the COI subcommittee, this individual's relationships, while it was determined that there is a low risk of confilct of intersest based on the content, a room monitor will be assigned as an extra precaution to ensure avoidance of bias. |
|------------------|---|---|---|
| Doeblin, Patrick | Speaker Right ventricular and left atrial strain predict volumetric response to cardiac resynchronization therapy / Speaker Rapid Fire 8 - Clinical Outcome and Prognosis III Kiosk 3 Right ventricular and left atrial strain predict volumetric response to cardiac resynchronization therapy | Philips (Other) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Emrich, Tilman | Role: Reviewer, Session: Rapid Fire 1 - Miscellaneous I Kiosk 4, Presentation: Changes of myocardial extracellular volume fraction measurements in acute versus chronic stage in a large animal infarct model | Siemens Healthineers, Circle Cardiovascular Imaging (Scientific/Medical Advisory Board Member) Siemens Healthineers (Speakers Bureau) Siemens Healthineers (Research Grant Site Principal Investigator) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of |

| | | | their roles on this program. |
|---------------------|--|---|---|
| Epstein, Frederick | Moderator Rapid Fire 8 - Tissue Characterization III Kiosk 4 | Siemens (Research Grant Site Principal Investigator) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Friedrich, Matthias | Role: Speaker, Session: Physician Preconference Session 3: Mapping and non-ischemic heart disease I, Presentation: Applications in Myocarditis | Area19 Medical Inc. (Private Stock Shareholder) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Garg, Pankaj | Role: Reviewer, Session: Rapid Fire 4 - Clinical Outcome and Prognosis I Kiosk 3, Presentation: Rapid | Anteris (Consultant) Edwards Lifesciences (Consultant) | Upon review by the COI subcommittee, this individual's relationships, while it was determined that there is a low risk of confilct of intersest based on the content, |

| | Fire 4 - Clinical Outcome and Prognosis I Kiosk 3 | | a room monitor will be assigned as an extra precaution to ensure avoidance of bias. |
|----------------|--|---|---|
| Gulati, Martha | Closing Plenary and Awards | Merck (Other); New Amsterdam (Scientific/Medical Advisory Board Member); Novartis (Scientific/Medical Advisory Board Member); Esperion (Scientific/Medical Advisory Board Member) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Hsiao, Albert | Role: Speaker, Session: Science Session 3: Artificial Intelligence in CMR, Presentation: What does it take for a clinician to use Al in CMR? | GE Healthcare (Research Grant Site Principal Investigator) Canon (Speakers Bureau) Tempus AI (Consultant) Bayer AG (Research Grant Site Principal Investigator) | An independent monitor will be assigned to this presentation to ensure unbiased presentation. |
| Johnson, Jason | Speaker, Moderator Best Case SCMR – is only a moderator. Is this an award session? | Abbott Medical (Consultant) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of |

| derator Rapid Fire 8- | Bauer (Research Grant Site | Upon review by the COI subcommittee, |
|----------------------------------|----------------------------|---|
| tue Characterization III sk 4 | Principal Investigator) | this individual's relationships were not perceived to present a conflict of interest in their role as a moderator. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| υ | | ne Characterization III Principal Investigator) |

Kramer, Christopher Role: Reviewer, Session: Clinical & Translation 6: CMR Workflow Efficiency -Debate, Presentation: Clinical & Translation 6: CMR Workflow Efficiency -Debate Discussion | Role: Reviewer, Session: Early Career Session 3: Navigating Future Landscapes: Building Teams, Career, and Integrating Innovations in CMR, Presentation: Building and Leading a High-Performance CMR Team Role: Speaker, Session: Clinical & Translation 6: CMR Workflow Efficiency -Debate, Presentation: Clinical & Translation 6: CMR Workflow Efficiency -Debate Discussion | Role: Speaker, Session: Early Career Session 3: Navigating Future Landscapes: Building Teams, Career, and Integrating Innovations in

BMS (Research Grant Site
Principal Investigator) |
Cytokinetics (Research Grant
Site Principal Investigator) |
Cytokinetics (Scientific/Medical
Advisory Board Member) |
Biomarin (Consultant)

Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program.

| | CMR, Presentation: Building and Leading a High-Performance CMR Team | | |
|----------------|---|--|--|
| Kwong, Raymond | Role: Speaker, Session: Late Breaking Clinical Trials, Presentation: Strong Association of Stress Cardiac Magnetic Resonance Ischemia Burden with Cardiovascular Events: Post-hoc Analysis from the | Bayer (Consultant) Alynlam, Cytokinetics, Bristol Myers Squibb (Research Grant Site Principal Investigator) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of |

| | ISCHEMIA Trial Role: Speaker, Session: SCMR Registry, Presentation: The GCMR Registry | | their roles on this program. |
|------------------|---|--|---|
| Larson, Peder | Science Session 5: Oxygenation and Metabolic Imaging with CMR Metabolic Imaging: Feeding the beast | GE Healthcare (Research Grant Site Principal Investigator); Imaginostics (Scientific/Medical Advisory Board Member); Myka Labs, Imaginostics (Consultant) | An independent monitor will be assigned to this presentation to ensure unbiased presentation. |
| Leiner, Tim | Speaker, Co-Author, Panelist AI in CMR analysis and diagnosis Clinical & Translation 5: Clinical Integration of AI in CMR (joint with ESCR) | Philips Healthcare (Consultant) Philips Healthcare (Research Grant Overall Principal Investigator) Philips Healthcare (Scientific/Medical Advisory Board Member) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Luetkens, Julian | Role: Reviewer, Session: Rapid Fire 9 - Interventional MRI & Miscellaneous Kiosk 5, Presentation: Rapid Fire | Novartis (Speakers Bureau) Philips Healthcare (Speakers Bureau) Bayer Healthcare (Consultant) Siemens | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several |

| | 9 - Interventional MRI & Miscellaneous Kiosk 5 | Healthineers (Speakers Bureau) GE Healthcare (Speakers Bureau) | statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
|--------------------|--|---|---|
| Manisty, Charlotte | Role: Speaker, Session: Early Career Session 1: Launch Your CMR Career: Funding and Research, Presentation: Pearls of Wisdom for Clinician Scientists in CMR | MycardiumAI (Corporate Board Member) Pfizer (Speakers Bureau) Abbott St Jude Medical (Speakers Bureau) Biotronik (Consultant) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Manka, Robert | Role: Speaker, Planning Committee, Session: Clinical & Translation 9: CMR Trials, Presentation: Clinical & Translation 9: CMR Trials | Philips Healthcare/Tomtec Imaging (Speakers Bureau) Bayer (Schweiz) AG (Speakers Bureau) Siemens (Speakers Bureau) Bristol Myers Squibb (Speakers Bureau) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| Markl, Michael | Role: Planning Committee, | Siemens (Research Grant Site | Upon review by the COI subcommittee, |
|----------------|------------------------------|---------------------------------|--|
| | Session: CMR: Innovations: | Principal Investigator) Third | this individual's relationships were not |
| | SCMR-MICCAI Joint Sessions | Coast Dynamics (Owner) | perceived to present a conflict of interest. |
| | on CMR Reconstruction | | They were asked to attest to several |
| | Challenge – Part 1, | | statements regarding adherence to |
| | Presentation: Introduction | | ACCME standards and guidelines, to |
| | to MICCAI CMR | | make full disclosure to learners, and to |
| | reconstruction challenge | | avoid any perception of bias in any of |
| | Role: Planning Committee, | | their roles on this program. |
| | Session: Clinical & | | |
| | Translation 2: Climate | | |
| | Change, Environmental | | |
| | Sustainability and CMR, | | |
| | Presentation: Clinical & | | |
| | Translation 2: Climate | | |
| | Change, Environmental | | |
| | Sustainability and CMR | | |
| | Role: Planning Committee, | | |
| | Session: Closing Plenary and | | |
| | Awards, Presentation: | | |
| | Closing Role: Planning | | |
| | Committee, Session: Closing | | |
| | Plenary and Awards, | | |
| | Presentation: Closing | | |
| | Plenary and Awards Role: | | |
| | Planning Committee, | | |
| | Session: Focus Session: | | |

Sustainable CMR, Presentation: Focus Session: Sustainable CMR | Role: Planning Committee, Session: Keynote Address, Gold Medal and Gold Medal Award, Presentation: 2025 Gold Medal Awards | Role: Planning Committee, Session: Keynote Address, Gold Medal and Gold Medal Award, Presentation: Introduction to Gold Medalist Prof Raad Mohiaddin | Role: Planning Committee, Session: Keynote Address, Gold Medal and Gold Medal Award. Presentation: Keynote Address, Gold Medal and Gold Medal Award | Role: Planning Committee, Session: Opening Plenary Session, Presentation: Opening Plenary Session Role: Planning Committee, Session: Opening Plenary

Session, Presentation: President Talk | Role: Planning Committee, Session: Opening Plenary Session, Presentation: Welcome to SCMR 2025 Role: Planning Committee, Session: SCMR Annual Assembly, Presentation: Concluding Remarks | Role: Planning Committee, Session: SCMR Annual Assembly, Presentation: Educational Program 2025-2026 | Role: Planning Committee, Session: SCMR Annual Assembly, Presentation: Open Discussion | Role: Planning Committee, Session: SCMR Annual Assembly, Presentation: Welcome & Call to Order Role: Speaker, Session: CMR: Innovations: SCMR-MICCAI Joint Sessions on CMR Reconstruction Challenge -

Part 1, Presentation: Introduction to MICCAI CMR reconstruction challenge Role: Speaker, Session: Clinical & Translation 2: Climate Change, Environmental Sustainability and CMR, Presentation: Clinical & Translation 2: Climate Change, Environmental Sustainability and CMR | Role: Speaker, Session: Closing Plenary and Awards, Presentation: Closing | Role: Speaker, Session: Closing Plenary and Awards, Presentation: Closing Plenary and Awards | Role: Speaker, Session: Focus Session: Sustainable CMR, Presentation: Focus Session: Sustainable CMR Role: Speaker, Session: Keynote Address, Gold Medal and Gold Medal Award, Presentation: 2025 Gold Medal Awards | Role:

Speaker, Session: Keynote Address, Gold Medal and Gold Medal Award. Presentation: Introduction to Gold Medalist Prof Raad Mohiaddin | Role: Speaker, Session: Keynote Address, Gold Medal and Gold Medal Award, Presentation: Keynote Address, Gold Medal and Gold Medal Award | Role: Speaker, Session: Opening Plenary Session, Presentation: Opening Plenary Session Role: Speaker, Session: Opening Plenary Session, Presentation: President Talk | Role: Speaker, Session: Opening Plenary Session, Presentation: Welcome to SCMR 2025 | Role: Speaker, Session: SCMR Annual Assembly, Presentation: Concluding Remarks | Role: Speaker, Session: SCMR Annual Assembly,

| Michos, Erin | Speaker/CMR in Women: Trials, Tribulations, & Global Insights | Amgen, Arrowhead, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Life Science, Esperion, Ionis, Eli | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several |
|--------------|---|---|---|
| | Program 2025-2026 Role: Speaker, Session: SCMR Annual Assembly, Presentation: Open Discussion Role: Speaker, Session: SCMR Annual Assembly, Presentation: Welcome & Call to Order | | |

| | | Nordisk, and Zoll - Consultant for all | make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
|----------------------|---|--|---|
| Muscogiuri, Giuseppe | Early Career Session 3: Navigating Future Landscapes: Building Teams, Career, and Integrating Innovations in CMR CMR Practice and Research in 2025: Integrating AI and LLMs | CASIS (Private Stock Shareholder) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Nagel, Eike | Speaker: Rapid Fire 1- Miscellaneous I Kiosk 4 Native T1 is independently predictive of aerobic functional capacity by VO2max in long-term follow-up of individuals with mild initial COVID disease /Speaker: Rapid Fire 6- Multi-Center Trials and Epidemiological Studies Kiosk 2 DECIPHER-HFPEF (DZHK 12): Normalization of T1 and T2 maps using | Bayer (Research Grant Overall Principal Investigator); Bayer (Consultant); Goethe CVI (Owner) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| | travelling volunteers | | |
|-----------------|---|--|---|
| Ng, Ming Yen | Speaker, Planner, Planning Committee, Moderator Precon/Congenital | GE Healthcare (Other) BAYER (Other) Boehringer Ingelheim (Speakers Bureau) Phantomics (Speakers Bureau) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Nijveldt, Robin | Role: Reviewer, Session: Rapid Fire 8 - Non-ischemic Primary and Secondary Cardiomyopathy III Kiosk 6, Presentation: Rapid Fire 8 - Non-ischemic Primary and Secondary Cardiomyopathy III kiosk 6 | Philips Volcano (Research Grant Site Principal Investigator) Biotronik (Research Grant Site Principal Investigator) BMS (Consultant) | The presentation was reviewed for potential bias. A room monitor was also assigned as an additional precaution. |

| O'Regan, Declan | Role: Reviewer, Moderator, Session: Rapid Fire 7- Machine Learning and Artificial Intelligence IV Kiosk 5, Presentation: Rapid Fire 7- Machine Learning and Artificial Intelligence IV Kiosk 5 | Bayer (Research Grant Overall Principal Investigator) Bayer (Consultant) BMS (Consultant) Calico (Research Grant Overall Principal Investigator) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest relative to their role as a reviewer. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
|-----------------|---|--|--|
| Patel, Amit | Role: Planning Committee, Session: Clinical & Translation 1: Multimodality imaging in Heart Failure and Transplantation (joint with ASE, ASNC and SCCT), Presentation: Role of multi- modality imaging in Heart Failure Role: Speaker, Planner, Chair, Moderator, Session: Clinical & Translation 1: Multimodality imaging in Heart Failure and Transplantation (joint with ASE, ASNC and SCCT), Presentation: Role of multi- modality imaging in Heart | GE Healthcare (Research Grant Overall Principal Investigator) Siemens Healthineers (Other) CircleCVI (Other) Neosoft (Other) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| | Failure Role: Speaker, Session: Clinical & Translation 1: Multimodality imaging in Heart Failure and Transplantation (joint with ASE, ASNC and SCCT), Presentation: Role of multi- modality imaging in Heart Failure | | |
|--------------------|--|---|---|
| Pettigrew, Roderic | Opening Plenary Session Expanding Boundaries | Siemens (Consultant); Resoundant (Corporate Board Member); StriveWorks (Scientific/Medical Advisory Board Member); Hyperfine (Scientific/Medical Advisory Board Member) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| Plein, Sven | Role: Speaker, Session: Focus Session: Efficient CMR, Presentation: Focus Session: Efficient CMR Role: Speaker, Session: Late Breaking Clinical Trials, Presentation: Late Breaking Clinical Trials | Philips (Speakers Bureau) Circle cvi (Speakers Bureau) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
|-------------------|--|--|---|
| Robinson, Joshua | Role: Planning Committee, Session: P/CHD Case Session, Presentation: P/CHD Case Session Role: Reviewer, Planning Committee, Session: P/CHD Case Session, Presentation: P/CHD Case Session | Siemens Medical Solutions USA, Inc (Consultant) Doximity, Inc (Public Stock Shareholder) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Rustamova, Yasmin | Late Breaking Clinical Trials The effect of Trimetazidine on the left ventricular global longitudinal strain assessed by cardiac magnetic resonance in stable angina patients and left ventricular dysfunction | Servier, Novartis (Research Grant Site Principal Investigator) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| Schwitter, Juerg | Role: Reviewer, Session: | Imricor SA (Research Grant | Upon review by the COI subcommittee, |
|------------------|-------------------------------|---------------------------------|---|
| | Rapid Fire 3 - Interventional | Site Principal Investigator) | this individual's relationships were not |
| | MRI Kiosk 6, Presentation: | Bayer Healthcare Schweiz AG | perceived to present a conflict of interest |
| | Training in a novel | (Research Grant Site Principal | relative to their role as a reviewer. They |
| | immersive catheter ablation | Investigator) | were asked to attest to several |
| | simulator using 3D MR | | statements regarding adherence to |
| | heart models of individual | | ACCME standards and guidelines, to |
| | patients improves | | make full disclosure to learners, and to |
| | performance of future | | avoid any perception of bias in any of |
| | electrophysiologists Role: | | their roles on this program. |
| | Reviewer, Session: Rapid Fire | | |
| | 7- Quantitative Perfusion II | | |
| | Kiosk 6, Presentation: Rapid | | |
| | Fire 7- Quantitative | | |
| | Perfusion II Kiosk 6 | | |
| Shah, Dipan | Role: Reviewer, Moderator, | Guerbet (Research Grant | Upon review by the COI subcommittee, |
| | speaker, Session: Late | Overall Principal Investigator) | this individual's relationships were not |
| | Breaking Clinical Trials, | Kiniksa (Speakers Bureau) | perceived to present a conflict of interest |
| | Presentation: Late Breaking | | relative to their role as a reviewer. They |
| | Clinical Trials Role: | | were asked to attest to several |
| | Reviewer, Moderator, | | statements regarding adherence to |
| | speaker, Session: Physician | | ACCME standards and guidelines, to |
| | Preconference Session 5: | | make full disclosure to learners, and to |
| | Flow and Valves, | | avoid any perception of bias in any of |
| | Presentation: | | their roles on this program. |
| | Aortic/pulmonic valve | | |
| | disease | | |

| Shenoy, Chetan | Speaker: Physician Preconference Session 3: Mapping and non-ischemic heart disease I Cardiomyopathy | Medtronic (Consultant) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
|--------------------|---|---|---|
| Shenoy, Chetan | Speaker: Rapid Fire 7- Clinical Outcome and Prognosis II Kiosk 3 | Medtronic (Consultant) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Simonetti, Orlando | Speaker: Focus Session: Accessible CMR Enhancing Equipment Accessibility in CMR with Lower-Field and Reduced Helium Usage | Siemens (Research Grant Overall Principal Investigator); Myocardial Solutions (Research Grant Site Principal Investigator); Cook Med Institute (Research Grant Site Principal Investigator); CALYX (Consultant) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| Soslow, Jonathan | Role: Speaker, Reviewer, | Sarepta (Consultant) Pfizer | The presentation was reviewed for |
|------------------|-----------------------------|--------------------------------|--|
| | Session: P/CHD | (Consultant) Immunoforge | potential bias. A room monitor was also |
| | Preconference Session 5: | (Consultant) Capricor | assigned as an additional precaution. |
| | Pediatric Cardiomyopathy, | (Consultant) Dyne | |
| | Presentation: DMD: new | (Consultant) Fibrogen | |
| | insights from CMR Role: | (Consultant) | |
| | Speaker, Reviewer, Session: | | |
| | Rapid Fire 2- | | |
| | Pediatric/Congenital Heart | | |
| | Disease II Kiosk 5, | | |
| | Presentation: Rapid Fire 2- | | |
| | Pediatric/Congenital Heart | | |
| | Disease II Kiosk 5 | | |
| Soulat, Gilles | CHD Abstract Session | GEHC (Research Grant Site | The presentation was reviewed for |
| | Speaker 4D flow evaluation | Principal Investigator) | potential bias. A room monitor was also |
| | of right and left diastolic | Siemens Healthineers (Research | assigned as an additional precaution. |
| | function in adult patient | Grant Site Principal | |
| | with repaired tetralogy of | Investigator) | |
| | Fallot. | | |
| Wallace, Tess | Speaker: Rapid Fire 9- | Siemens Medical Solutions | Upon review by the COI subcommittee, |
| | Interventional MRI & | USA, Inc. (Employee) | this individual's relationships were not |
| | Miscellaneous Kiosk 5 Late | | perceived to present a conflict of interest. |
| | Gadolinium Enhancement | | They were asked to attest to several |
| | with Fat-Water Separation | | statements regarding adherence to |
| | in Patients with MRI- | | ACCME standards and guidelines, to |
| | Conditional Cardiac | | make full disclosure to learners, and to |
| | Implantable Electronic | | avoid any perception of bias in any of |

| | Devices at 3T | | their roles on this program. |
|----------------|---|--|---|
| Weissman, Gaby | Role: Speaker, Moderator, Session: Read with the Experts Session 1: Ischemic Cardiomyopathy, Presentation: Microvascular obstruction | Abbott (Other) Medtronic (Other) Boston Scientific (Other) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |
| Wen, Ke | Oral Abstract Science #1- Advances in Cardiac MRI Techniques Comparative Evaluation of Third-Order Motion-Compensated in Vivo Diffusion Tensor CMR Across Cardiac Phases Using an Ultra-High-Gradient Strength Clinical Scanner | Siemens Healthineers (Other) | Upon review by the COI subcommittee, this individual's relationships were not perceived to present a conflict of interest. They were asked to attest to several statements regarding adherence to ACCME standards and guidelines, to make full disclosure to learners, and to avoid any perception of bias in any of their roles on this program. |

| Wendell, David | Role: Reviewer, Session: | Heart Imaging Technologies | Upon review by the COI subcommittee, |
|----------------|------------------------------|---------------------------------------|--|
| | Rapid Fire 1 - CAD: New | (Consultant) Siemens | this individual's relationships were not |
| | Methods Kiosk 2, | Healthineers (Patent Holder) | perceived to present a conflict of interest |
| | Presentation: Diagnostic | , , , , , , , , , , , , , , , , , , , | in their role as a reviewer. They were |
| | performance of black-blood | | asked to attest to several statements |
| | versus gray-blood delayed | | regarding adherence to ACCME standards |
| | enhancement imaging for | | and guidelines, to make full disclosure to |
| | the detection of myocardial | | learners, and to avoid any perception of |
| | infarction Role: Reviewer, | | bias in any of their roles on this program. |
| | Session: Rapid Fire 1- CAD: | | |
| | New Methods Kiosk 2, | | |
| | Presentation: Rapid Fire 1- | | |
| | CAD: New Methods Kiosk 2 | | |
| Wright, Graham | Speaker: Rapid Fire 9- | Siemens Healthineers (Research | Upon review by the COI subcommittee, |
| | Interventional MRI & | Grant Site Principal | this individual's relationships were not |
| | Miscellaneous Kiosk 5 | Investigator); ADAS 3D | perceived to present a conflict of interest. |
| | | (Research Grant Overall | They were asked to attest to several |
| | | Principal Investigator); Vista.ai | statements regarding adherence to |
| | | (Research Grant Overall | ACCME standards and guidelines, to |
| | | Principal Investigator) | make full disclosure to learners, and to |
| | | | avoid any perception of bias in any of |
| | | | their roles on this program. |
| Zakeri, Rosita | Speaker: Clinical & | AstraZeneca (Consultant); | Upon review by the COI subcommittee, |
| | Translation 8: Her Heart | Boehringer Ingelheim | this individual's relationships were not |
| | Unveiled: Exploring CMR in | (Consultant) | perceived to present a conflict of interest. |
| | Women's Heart Disease | | They were asked to attest to several |
| | HFpEF and microvascular | | statements regarding adherence to |

| disease | ACCME standards and guidelines, to |
|---------|--|
| | make full disclosure to learners, and to |
| | avoid any perception of bias in any of |
| | their roles on this program. |